Table 2.
Duration of follow-up and incidence of renal and mortality end points during the study period (n=139)
| Characteristic | Data Available, n (%) | Total Cohort (n=139) | Did Not Develop Composite End Point (n=83)a | Developed Composite End Point (n=56)a |
| Number of eGFR measurements, median (IQR) | 139 (100) | 22 (12–34) | 19 (11–29) | 27 (15–42) |
| Duration of renal functional follow-up (yr), median (IQR)b | 139 (100) | 4.7 (3.5–5.2) | 4.9 (4.1–5.2) | 4.1 (1.8–5.2) |
| Duration of study follow-up (yr), median (IQR)c | 139 (100) | 5.4 (4.7–5.7) | 5.4 (4.8–5.7) | 5.4 (4.4–5.7) |
| Slope of CKD-EPI eGFR (ml/min per BSA per yr), median (IQR)d | 129 (93) | −0.9 (−2.3 to 0.5) | 0 (−1 to 1.6) | −2.2 (−3.9 to −1.4) |
| ≥40% decrease in CKD-EPI eGFR, n (%) | 139 (100) | 38 (27) | 0 (0) | 38 (68) |
| Doubling of serum creatinine, n (%) | 139 (100) | 14 (10) | 0 (0) | 14 (25) |
| Required RRT, n (%) | 139 (100) | 21 (15) | 0 (0) | 21 (38) |
| Death from any cause, n (%) | 139 (100) | 15 (11) | 0 (0) | 15 (27) |
IQR, interquartile range; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; BSA, body surface area.
a
Composite end point: ≥40% decrease in CKD-EPI eGFR, doubling of serum creatinine, RRT, or mortality.
b
Duration between date of study enrollment and date of final eGFR determination. eGFR values subsequent to RRT initiation were excluded.
c
Duration between date of study enrollment and date of last study follow-up or date of death.
d
Slope of CKD-EPI eGFR was calculated only for individuals with three or more eGFR values over at least 1 year.